

Filed on behalf of: Par Pharmaceutical, Inc.

Entered: March 31, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioner

v.

NOVARTIS AG.

Patent Owner

Case IPR2016-00075

U.S. Patent No. 7,297,703

Before KAREN HILASKI, *Trial Paralegal*.

**PETITIONER'S TRANSMITTAL LETTER ACCOMPANYING
SUBMISSION OF EXHIBIT 1017**

Case IPR2016-00075
U.S. Patent No. 7,297,703

Pursuant to 37 C.F.R. § 42.6(e)(4)(ii) and the Board's March 29, 2016 email correspondence, Petitioner Par Pharmaceutical, Inc. respectfully submits the following exhibit in connection with the parties' Joint Motion to Terminate Proceedings Pursuant to 37 C.F.R. § 42.74 (Paper 8):

| Exhibit | Description |
|----------------|------------------------------------|
| 1017 | Covenant Not to Sue (Confidential) |

Respectfully submitted,

Dated: March 31, 2016

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005)
Latham & Watkins LLP
885 Third Avenue
New York, NY 10022-4834
212-906-1200; 212-751-4864 (Fax)

*Counsel for Petitioner
Par Pharmaceutical, Inc.*

Case IPR2016-00075
U.S. Patent No. 7,297,703

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 31st day of March, 2016, a true and correct copy of the foregoing **PETITIONER'S UPDATED EXHIBIT LIST** was served by electronic mail on Patent Owner's lead and backup counsel at the following email address:

Nicholas N. Kallas (Reg. No. 31,530)
Raymond R. Mandra (Reg. No. 34,382)
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104-3800
ZortressAfinitorIPR@fchs.com

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005)
Latham & Watkins LLP
885 Third Avenue
New York, NY 10022-4834
212-906-1200; 212-751-4864 (Fax)

Counsel for Petitioner